After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA methylation regulate gene expression in health and disease. In a collection of eight papers published in Science and Science Advances, researchers describe how they have applied single-cell level multi-omics data and tools and techniques developed in the first part of the 4D Nucleome program to track changes in the noncoding part of the genome that are involved in heart disease, Alzheimer’s disease, brain aging, retinal health and immune cell development. Read More
Monkeypox virus (MPXV), which causes mpox disease in humans, comprises two clades: the Central African clade I (with a case fatality rate of about 11%) and the West African clade II (with a case fatality rate of about 4%). The differences in virulence among MPXV clades in humans warrant further investigation; however, a critical gap is the lack of small-animal models for comparing IIa vs. IIb clades. Read More
Thyora Therapeutics has launched with a mission to leverage next-generation covalent chemistry to accelerate clinical translation and create therapies for unmet medical needs. Read More
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism spectrum disorder and facioscapulohumeral muscular dystrophy programs. The company’s pipeline also includes programs for myotonic dystrophy and Huntington’s disease. Read More
A recent Beone Medicines I GmbH and Beone Pharmaceutical (Suzhou) Co. Ltd. patent describes new 4-substituted fused bicyclic heteroaryl derivatives acting as Kelch-like ECH-associated protein 1 (Keap1)/CUL3 interaction inducers reported to be useful for the treatment of cancer. Read More
HCW Biologics Inc. has requested a type B (pre-IND) meeting with the FDA to discuss the development and regulatory strategy for its investigational tetravalent T-cell engager (TCE), HCW-11-018b, for solid tumors. Read More
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain penetration designed for the treatment of Parkinson’s disease. Read More
Zonsen Peplib Biotech Inc. has synthesized new peptide-drug conjugates comprising a glypican-3 (GPC3)-targeting peptide covalently linked to a payload potentially useful for the treatment of cancer. Read More
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged new antibody-drug conjugates comprising antibodies targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA; CD66e) covalently linked to a cytotoxic drug potentially useful for the treatment of colorectal cancer. Read More
Apertura Gene Therapy LLC has announced its participation in a consortium selected to receive funding from the Advanced Research Projects Agency for Health (ARPA-H) THRIVE program to develop gene therapies for rare childhood diseases. Read More
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has patented new gastric inhibitory polypeptide receptor (GIPR) antagonists potentially useful for the treatment of metabolic diseases. Read More
Bioray Pharmaceutical Co. Ltd. has prepared and tested new antibody-drug conjugates consisting of antibodies covalently linked to payloads. They are reported to be potentially useful for the treatment of cancer, infections, inflammatory and immunological disorders. Read More
Sprint Bioscience AB has entered into an agreement to use Lilly Tunelab, Eli Lilly and Co.’s AI-based drug discovery platform, to support work on its research portfolio. Read More
